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Abstract Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare, progressive,
life-threatening, hereditary disorder caused by mutations in the transthyretin gene and
characterized by extracellular deposition of transthyretin-derived amyloid fibrils in peripheral
and autonomic nerves, heart, and other organs. TTR-FAP is frequently diagnosed late
because the disease is difficult to recognize due to phenotypic heterogeneity. Based
on published literature and expert opinion, symptom clusters suggesting TTR-FAP are
reviewed, and practical guidance to facilitate earlier diagnosis is provided. TTR-FAP
should be suspected if progressive peripheral sensory-motor neuropathy is observed in
combination with one or more of the following: family history of a neuropathy, autonomic
dysfunction, cardiac hypertrophy, gastrointestinal problems, inexplicable weight loss, carpal
tunnel syndrome, renal impairment, or ocular involvement. If TTR-FAP is suspected,
transthyretin genotyping, confirmation of amyloid in tissue biopsy, large- and small-fiber
assessment by nerve conduction studies and autonomic system evaluations, and cardiac
testing should be performed.
Key words: diagnosis, hereditary amyloidosis, transthyretin, transthyretin familial amyloid
neuropathy
Introduction
Transthyretin familial amyloid polyneuropathy
(TTR-FAP) is an autosomal-dominant, adult-onset disor-
der associated with over 100 different mutations in the
transthyretin (TTR) gene that cause transthyretin pro-
tein to deposit as amyloid in peripheral and autonomic
nerves, heart, gastrointestinal (GI) tract, kidneys,
eyes, and connective tissue of the transversal carpal
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ligament (Ando et al., 2013; Rowczenio et al., 2014;
Sekijima, 2015). This results in progressive organ
dysfunction and death within an average of 10 years
(Ando et al., 2013).
TTR-FAP is a highly heterogeneous disease asso-
ciated with a wide range of clinical manifestations
that may present in varying degrees and combinations
(Ando et al., 2013; Sekijima, 2015). It is frequently dom-
inated by progressive and relentless peripheral nerve
damage. The disease can be difficult to recognize due
to its variable clinical presentation and non-specific
symptoms. The age of onset ranges from the sec-
ond to ninth decade of life (Ando et al., 2013), and
incomplete penetrance of clinical disease can lead
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to sporadic cases without known affected relatives.
Accurate diagnosis of TTR-FAP is often delayed for
years (Planté-Bordeneuve et al., 2007; Koike et al.,
2011; Dohrn et al., 2013; Adams et al., 2014). Making
an accurate diagnosis is important to permit effec-
tive disease management, as tissue damage is largely
irreversible, and available treatment options are most
beneficial in early disease stages (Coelho et al., 2013;
Planté-Bordeneuve, 2014; Ericzon et al., 2015). This per-
spective provides practical guidance on early detection
of TTR-FAP.
Clinical Features of TTR-FAP
Typical clinical symptoms associated with TTR-FAP
are illustrated in Fig. 1. A particular challenge in making
a diagnosis is that clinical manifestations are not
necessarily uniform among carriers of the same TTR
mutation and can vary even within the same family
(Ando et al., 2013). The clinical phenotype is also
influenced by genetic, epigenetic, or environmental
factors other than the TTR mutation (see Table 1).
The pattern of amyloid deposition may also play a role
(Bergström et al., 2005; Ihse et al., 2013).
Length-dependent peripheral sensory-motor
neuropathy is a hallmark feature of TTR-FAP. In
classical early-onset (<50 years of age) Val30Met
TTR-FAP (Andrade, 1952), distal small myelinated and
unmyelinated nerve fibers associated with pain and
temperature sensation become damaged first, which
may manifest as paresthesia, dysesthesia, allodynia,
hyperalgesia, or spontaneous pain in the feet. Axonal
degeneration then progresses relentlessly in a distal
to proximal pattern reaching upper limbs usually 4
to 5 years after first symptoms. Within a few years,
larger myelinated sensory and motor nerve fibers
become affected and impairment of light touch, vibra-
tion, and position sensation, and motor deficit appear
in the distal lower limbs. Motor deficits also follow
a length-dependent progression, causing increasing
walking difficulty and weakness.
Late-onset cases are characterized by relative
preservation of unmyelinated nerve fibers and conspic-
uous presence of axonal sprouting (Koike et al., 2004).
These characteristics are responsible for impaired
superficial and deep sensation, severe neuropathic
pain, early distal motor involvement, and relatively mild
autonomic symptoms (Conceição and De Carvalho,
2007; Koike et al., 2011).
Common Diagnostic Pitfalls
The length-dependent pattern of symmetric
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Figure 1. Clinical features associated with TTR-FAP. CNS,
central nervous system; GI, gastrointestinal.
TTR-FAP is not unique, and similar neurologic impair-
ments can be observed in many conditions, all of
which can mislead clinical diagnosis.
The most common neuropathic misdiagnosis for
sporadic TTR-FAP is chronic inflammatory demyelinat-
ing polyneuropathy (CIDP) (Planté-Bordeneuve, 2014).
For instance, 20% of 90 French patients without a
family history of TTR-FAP (Planté-Bordeneuve et al.,
2007) and 53% of 15 Japanese patients with spo-
radic V30M TTR-FAP (Koike et al., 2011) were initially
misdiagnosed with CIDP. Although CIDP is generally
characterized by a demyelinating sensory-motor neu-
ropathy, once extensive axonal length-dependent dam-
age is present, electrophysiological characteristics of
TTR-FAP can resemble those of CIDP due to sec-
ondary demyelination. Furthermore, protein levels in
cerebrospinal fluid can be elevated in patients with
TTR-FAP, albeit less markedly than in CIDP. In some
cases, a negative biopsy contributed to misdiagnosis.
Given the frequent misdiagnosis, there should be a
high suspicion index for TTR-FAP in patients diagnosed
with CIDP that do not respond to immunomodulatory
treatment.
There have been numerous cases where
TTR-related amyloidosis was initially misdiagnosed
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•  Rapid disease progression
•  Failure of response to prior therapies
+ ≥1 of thefollowing
Family history
Early autonomic dysfunction
(e.g., erectile dysfunction or postural hypotension)
Unexplained weight loss
Cardiac hypertrophy, arrhythmias, ventricular
blocks, or cardiomyopathy
Bilateral carpal tunnel syndrome
(especially if also present in family members)
Renal abnormalities
(e.g., albuminuria or mild azotemia)
Vitreous opacities
GI complaints
(e.g., chronic diarrhea, constipation, or diarrhea/constipation)
Figure 2. Potential “red-flag” symptom clusters that may warn of a diagnosis of transthyretin familial amyloid polyneuropathy
(TTR-FAP).
as amyloid light-chain (AL) amyloidosis (Cowan
et al., 2011; Briani et al., 2012). Misdiagnosis can
be due to occurrence of monoclonal gammopathy in
elderly patients or false immunolabeling of amyloid
deposits, leading to inappropriate, potentially harmful
chemotherapeutic treatment. This can be avoided by
careful typing of the amyloid precursor protein.
TTR-FAP is unlikely to be mistaken for other forms
of hereditary amyloid neuropathy caused by mutation
of the apolipoprotein A-I, gelsolin, or 𝛽2-microglobulin
genes. However, although very rare and less rapidly
progressive, hereditary neuropathy due to truncation
mutations of the prion protein can closely mimic
TTR-FAP (Mead and Reilly, 2015) and should be con-
sidered in the differential diagnosis.
“Red-flag” Symptom Combinations That
May Warn of a Diagnosis of TTR-FAP
Characteristic features that can help identify
TTR-FAP are heritability and general multi-symptom
involvement. Consequently, it is important to obtain
a complete clinical history with details of symptoms
of systemic disease and a complete and detailed
family history (Ando et al., 2013; Planté-Bordeneuve,
2014). The occurrence of progressive peripheral
sensory-motor polyneuropathy and at least one of
the following is suggestive of TTR-FAP: family his-
tory of neuropathy, early autonomic dysfunction,
cardiac involvement, diarrhea, constipation, alternat-
ing episodes of constipation and diarrhea, inexplicable
weight loss, carpal tunnel syndrome, renal impairment,
or vitreous opacity (Fig. 2).
Of these combinations, peripheral neuropathy
with early autonomic signs, such as erectile dysfunc-
tion or GI symptoms, and peripheral neuropathy with
cardiac manifestations are the most common and
important combinations in sporadic patients. Rapid
disease progression (Dohrn et al., 2013) and failure
to respond to immunomodulatory treatment are
additional signs.
Core Diagnostic Tests to Identify
TTR-FAP
The clusters of clinical symptoms mentioned
above should raise suspicion of TTR-FAP, particularly
if there is a positive family history. In patients with
suspected TTR-FAP, TTR genotyping should be per-
formed. In sporadic cases, the entire coding region
of the TTR gene, that is all four exons, should be
sequenced. Tissue biopsy analysis and neurologic,
cardiac, autonomic, and ophthalmologic evaluation can
lend further credence to the correct diagnosis.
Acknowledgements
Medical writing support was provided by Susanne
Vidot, PhD, of Engage Scientific Solutions and was
8
Conceição et al. Journal of the Peripheral Nervous System 21:5–9 (2016)
funded by Pfizer. Dr. I. C. received support from Alny-
lam Pharmaceuticals, ISIS Pharmaceuticals, and Pfizer,
and serves on the THAOS scientific advisory board. Dr.
A. G.-D. received honoraria from Alnylam Pharmaceu-
ticals and Pfizer, and serves on the THAOS scientific
advisory board. Dr. L. O. received support from Alny-
lam Pharmaceuticals to attend scientific meetings and
honoraria from Pfizer. Dr. H. H.-J. S. received honoraria
from Pfizer. Drs. D. S., M.-L. O., and L. A. are employ-
ees of Pfizer.
References
Adams D, Théaudin M, Cauquil C, Algalarrondo V, Slama M
(2014). FAP neuropathy and emerging treatments. Curr Neu-
rol Neurosci Rep 14:435.
Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S,
Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said
G, Salvi F (2013). Guideline of transthyretin-related hereditary
amyloidosis for clinicians. Orphanet J Rare Dis 8:31.
Andrade C (1952). A peculiar form of peripheral neuropathy:
familiar atypical generalized amyloidosis with special involve-
ment of the peripheral nerves. Brain 75:408–427.
Bergström J, Gustavsson A, Hellman U, Sletten K, Murphy
CL, Weiss DT, Solomon A, Olofsson BO, Westermark P
(2005). Amyloid deposits in transthyretin-derived amyloido-
sis: cleaved transthyretin is associated with distinct amyloid
morphology. J Pathol 206:224–232.
Briani C, Cavallaro T, Ferrari S, Taioli F, Calamelli S, Verga L, Adami
F, Fabrizi GM (2012). Sporadic transthyretin amyloidosis
with a novel TTR gene mutation misdiagnosed as primary
amyloidosis. J Neurol 259:2226–2228.
Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V,
Suhr OB, Conceição I, Schmidt HH, Trigo P, Kelly JW, Labau-
diniere R, Chan J, Packman J, Grogan DR (2013). Long-term
effects of tafamidis for the treatment of transthyretin familial
amyloid polyneuropathy. J Neurol 260:2802–2814.
Conceição I, De Carvalho M (2007). Clinical variability in type
I familial amyloid polyneuropathy (Val30Met): comparison
between late- and early-onset cases in Portugal. Muscle
Nerve 35:116–118.
Coutinho P, da Silva AM, Lima JL, Barbosa AR (1980). Forty years
of experience with type I amyloid neuropathy. Review of 483
cases. Amyloid and Amyloidosis. Glenner GG, Costa PP, de
Freitas F. Excerpta Medica, Amsterdam, 88–98.
Cowan AJ, Skinner M, Berk JL, Sloan JM, O’Hara C, Seldin
DC, Sanchorawala V (2011). Macroglossia – not always AL
amyloidosis. Amyloid 18:83–86.
Dohrn MF, Röcken C, De Bleecker JL, Martin JJ, Vorgerd M,
Van den Bergh PY, Ferbert A, Hinderhofer K, Schröder JM,
Weis J, Schulz JB, Claeys KG (2013). Diagnostic hallmarks
and pitfalls in late-onset progressive transthyretin-related
amyloid-neuropathy. J Neurol 260:3093–3108.
Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou
A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D,
Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH,
Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y,
Heaton N, Otto G, Suhr O (2015). Liver transplantation for
hereditary transthyretin amyloidosis: after 20 years still the
best therapeutic alternative? Transplantation 99:1847–1854.
González-Duarte A, Lem-Carrillo M, Cárdenas-Soto K (2013).
Description of transthyretin S50A, S52P and G47A mutations
in familial amyloidosis polyneuropathy. Amyloid 20:221–225.
Ihse E, Rapezzi C, Merlini G, Benson MD, Ando Y, Suhr OB,
Ikeda S, Lavatelli F, Obici L, Quarta CC, Leone O, Jono H,
Ueda M, Lorenzini M, Liepnieks J, Ohshima T, Tasaki M,
Yamashita T, Westermark P (2013). Amyloid fibrils containing
fragmented ATTR may be the standard fibril composition in
ATTR amyloidosis. Amyloid 20:142–150.
Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E,
Yamamoto M, Hattori N, Sobue G (2002). Type I (transthyretin
Met30) familial amyloid polyneuropathy in Japan: early- vs
late-onset form. Arch Neurol 59:1771–1776.
Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto
M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G (2004).
Pathology of early- vs late-onset TTR Met30 familial amyloid
polyneuropathy. Neurology 63:129–138.
Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M,
Tanaka F, Sobue G (2011). Diagnosis of sporadic transthyretin
Val30Met familial amyloid polyneuropathy: a practical analy-
sis. Amyloid 18:53–62.
Mead S, Reilly MM (2015). A new prion disease: relationship with
central and peripheral amyloidoses. Nat Rev Neurol 11:90–97.
Planté-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D,
Lacroix C, Said G (1998). Genotypic-phenotypic variations in
a series of 65 patients with familial amyloid polyneuropathy.
Neurology 51:708–714.
Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C,
Adams D, Said G (2007). Diagnostic pitfalls in sporadic
transthyretin familial amyloid polyneuropathy (TTR-FAP). Neu-
rology 69:693–698.
Planté-Bordeneuve V (2014). Update in the diagnosis and man-
agement of transthyretin familial amyloid polyneuropathy.
J Neurol 261:1227–1233.
Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C,
Hawkins PN, Obici L, Westermark P, Grateau G, Wechalekar
AD (2014). Online registry for mutations in hereditary amyloi-
dosis including nomenclature recommendations. Hum Mutat
35:E2403–E2412.
Sekijima Y (2015). Transthyretin (ATTR) amyloidosis: clinical
spectrum, molecular pathogenesis and disease-modifying
treatments. J Neurol Neurosurg Psychiatry 86:1036–1043.
9
